for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ocuphire Pharma Inc

OCUP.OQ

Latest Trade

4.20USD

Change

-0.11(-2.55%)

Volume

58,405

Today's Range

4.20

 - 

4.36

52 Week Range

3.70

 - 

13.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Ocuphire Announces Financial Results For The First Quarter 2021

May 7 (Reuters) - Ocuphire Pharma Inc <OCUP.O>::OCUPHIRE ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2021 AND PROVIDES CORPORATE UPDATE.Q1 ADJUSTED NON-GAAP LOSS PER SHARE $0.47.QTRLY LOSS PER SHARE $3.57.

Mina Sooch Reports A 11.8% Passive Stake In Ocuphire Pharma Inc As Of December 31, 2020 - SEC Filing

March 17 (Reuters) - Ocuphire Pharma Inc <OCUP.O>::MINA SOOCH REPORTS A 11.8% PASSIVE STAKE IN OCUPHIRE PHARMA INC AS OF DECEMBER 31, 2020 - SEC FILING.

Ocuphire Pharma Says Entered Into Capital On Demand Sales Agreement With JonesTrading Institutional Services

March 11 (Reuters) - Ocuphire Pharma Inc <OCUP.O>::OCUPHIRE PHARMA INC SAYS ENTERED INTO CAPITAL ON DEMANDTM SALES AGREEMENT WITH JONESTRADING INSTITUTIONAL SERVICES LLC - SEC FILING.OCUPHIRE PHARMA INC SAYS MAY OFFER AND SELL SHARES OF COMMON STOCK OF UP TO $40 MILLION.

Ocuphire Pharma Files For Mixed Shelf Of Upto $125 Million

Feb 4 (Reuters) - Ocuphire Pharma Inc <OCUP.O>::OCUPHIRE PHARMA INC FILES FOR MIXED SHELF OF UPTO $125 MILLION - SEC FILING.OCUPHIRE PHARMA INC SAYS IN ADDITION, OFFERING OF UP TO 6.99 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS.

Rexahn Says Co And Ocuphire Enter Into Definitive Merger Agreement

June 17 (Reuters) - Rexahn Pharmaceuticals Inc <REXN.O>::REXAHN AND OCUPHIRE ENTER INTO DEFINITIVE MERGER AGREEMENT.$21.15 MILLION INVESTMENT COMMITTED BY INSTITUTIONAL HEALTHCARE AND ACCREDITED INVESTORS.COMBINED CO TO CHANGE NAME TO OCUPHIRE PHARMA AND IS EXPECTED TO TRADE ON NASDAQ CAPITAL MARKET UNDER TICKER SYMBOL "OCUP.".FOLLOWING CLOSING, REXAHN WILL ISSUE WARRANTS TO PURCHASE SHARES OF CO'S COMMON STOCK, ADDITIONAL SHARES OF REXAHN COMMON STOCK.FOLLOWING MERGER, MINA SOOCH WILL BE APPOINTED COMBINED CO'S PRESIDENT AND CHIEF EXECUTIVE OFFICER.

Rexahn Pharmaceuticals Says On Feb 8, Co Entered Into Exclusive License Agreement With Zhejiang Haichang Biotechnology

Feb 10 (Reuters) - Rexahn Pharmaceuticals Inc <REXN.O>::REXAHN PHARMACEUTICALS - ON FEB 8, CO ENTERED INTO EXCLUSIVE LICENSE AGREEMENT WITH ZHEJIANG HAICHANG BIOTECHNOLOGY.REXAHN - HAICHANG WILL PAY CO DEVELOPMENT MILESTONE PAYMENTS OF UP TO $63 MILLION WITH RESPECT TO RX-0201 & RX-0301, UP TO $33 MILLION WITH RESPECT TO RX-0047.REXAHN -CO GRANTED HAICHANG EXCLUSIVE SUBLICENSABLE WORLDWIDE LICENSE TO RESEARCH, DEVELOP, COMMERCIALIZE PRODUCTS COMPRISING RX-0201,RX-0301, RX-0047.

Rexahn Says Potential Strategic Alternatives That May Be Explored Include Acquisition, Merger, Reverse Merger

Sept 24 (Reuters) - Rexahn Pharmaceuticals Inc <REXN.O>::REXAHN TO EXPLORE STRATEGIC ALTERNATIVES.REXAHN PHARMACEUTICALS INC - REXAHN HAS ENGAGED OPPENHEIMER & CO., INC. AS ITS FINANCIAL ADVISOR TO ASSIST IN THIS PROCESS..REXAHN PHARMACEUTICALS INC - EVALUATING OPPORTUNITIES TO EXTEND ITS RESOURCES AND HAS REDUCED ITS STAFF BY TWO POSITIONS.REXAHN PHARMACEUTICALS - POTENTIAL STRATEGIC ALTERNATIVES THAT MAY BE EXPLORED INCLUDE AN ACQUISITION, MERGER, REVERSE MERGER.REXAHN PHARMACEUTICALS INC - PROJECTING A YEAR-END 2019 BALANCE OF CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF BETWEEN $10 MILLION AND $12 MILLION.REXAHN - POTENTIAL STRATEGIC ALTERNATIVES THAT MAY BE EXPLORED INCLUDE SALES OF ASSETS, LICENSING OR OTHER STRATEGIC TRANSACTIONS.REXAHN PHARMACEUTICALS INC - CO ANTICIPATES HAVING FIVE EMPLOYEES AS OF OCTOBER 1.

Rexahn Pharmaceuticals Reports Q2 LOSS PER SHARE $0.61

Aug 7 (Reuters) - Rexahn Pharmaceuticals Inc RNN.A::REXAHN PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES UPDATE ON RX-3117 DEVELOPMENT.Q2 LOSS PER SHARE $0.61.Q2 EARNINGS PER SHARE ESTIMATE $-0.85 -- REFINITIV IBES DATA.AS OF AUGUST 7, 2019, HAD APPROXIMATELY $15.3 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (UNAUDITED).REXAHN PHARMACEUTICALS - EXPECTS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND FOR AT LEAST NEXT 12 MONTHS.

Rexahn Announces Move To Nasdaq

May 28 (Reuters) - Rexahn Pharmaceuticals Inc <RNN.A>::REXAHN ANNOUNCES MOVE TO NASDAQ.REXAHN PHARMACEUTICALS INC - WILL VOLUNTARILY TRANSFER ITS STOCK EXCHANGE LISTING TO NASDAQ CAPITAL MARKET FROM ITS CURRENT LISTING ON NYSE AMERICAN.REXAHN PHARMACEUTICALS INC - EXPECTS TO BEGIN TRADING ON NASDAQ UNDER SYMBOL "REXN" ON OR ABOUT JUNE 10, 2019.REXAHN PHARMACEUTICALS INC - COMPANY'S COMMON STOCK WILL CONTINUE TRADING ON NYSE AMERICAN UNDER SYMBOL "RNN" UNTIL MOVE IS COMPLETED.

Rexahn Pharmaceuticals Q1 Loss Per Share $0.62

May 13 (Reuters) - Rexahn Pharmaceuticals Inc <RNN.A>::REXAHN PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.62.Q1 EARNINGS PER SHARE ESTIMATE $-0.93 -- REFINITIV IBES DATA.AS OF MAY 10, 2019, HAD $18.3 MILLION IN CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES (UNAUDITED).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up